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Background: The capacity of the recombinant Vaccinia virus GLV-1h68 as a single agent to efficiently treat different
human or canine cancers has been shown in several preclinical studies. Currently, its human safety and efficacy are
investigated in phase I/II clinical trials. In this study we set out to evaluate the oncolytic activity of GLV-1h68 in
the human lung adenocarcinoma cell line PC14PE6-RFP in cell cultures and analyzed the antitumor potency of
a combined treatment strategy consisting of GLV-1h68 and cyclophosphamide (CPA) in a mouse model of
PC14PE6-RFP lung adenocarcinoma.
Methods: PC14PE6-RFP cells were treated in cell culture with GLV-1h68. Viral replication and cell survival were
determined by plaque assays and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays, respectively.
Subcutaneously implanted PC14PE6-RFP xenografts were treated by systemic injection of GLV-1h68, CPA or a
combination of both. Tumor growth and viral biodistribution were monitored and immune-related antigen profiling
of tumor lysates was performed.
Results: GLV-1h68 efficiently infected, replicated in and lysed human PC14PE6-RFP cells in cell cultures. PC14PE6-RFP
tumors were efficiently colonized by GLV-1h68 leading to much delayed tumor growth in PC14PE6-RFP tumor-bearing
nude mice. Combination treatment with GLV-1h68 and CPA significantly improved the antitumor efficacy of GLV-1h68
and led to an increased viral distribution within the tumors. Pro-inflammatory cytokines and chemokines were distinctly
elevated in tumors of GLV-1h68-treated mice. Factors expressed by endothelial cells or present in the blood were
decreased after combination treatment. A complete loss in the hemorrhagic phenotype of the PC14PE6-RFP tumors
and a decrease in the number of blood vessels after combination treatment could be observed.
Conclusions: CPA and GLV-1h68 have synergistic antitumor effects on PC14PE6-RFP xenografts. We strongly suppose
that in the PC14PE6-RFP model the enhanced tumor growth inhibition achieved by combining GLV-1h68 with CPA is
due to an effect on the vasculature rather than an immunosuppressive action of CPA. These results provide evidence
to support further preclinical studies of combining GLV-1h68 and CPA in other highly angiogenic tumor models.
Moreover, data presented here demonstrate that CPA can be combined successfully with GLV-1h68 based oncolytic
virus therapy and therefore might be promising as combination therapy in human clinical trials.
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Lung cancer still represents a very fatal disease causing
the majority of the cancer-related deaths in males world-
wide [1]. Non-small cell lung cancer (NSCLC), including
adenocarcinoma, squamous cell carcinoma, and large
cell carcinoma, constitutes 80-85% of all lung cancers,
whereas small cell lung cancer accounts for 15% to 20%,
with most patients having advanced inoperable disease
at the time of diagnosis. The current treatment options are
surgical resection, platinum-based doublet chemotherapy,
and radiation therapy alone or in combination [2]. How-
ever, the prognosis for lung cancer patients still remains
poor with an overall 5-year survival rate of only 15% [3].
Therefore, new, effective, therapeutic approaches for lung
cancer are mandatory. One novel strategy represents the
targeted therapy. Therein drugs are applied that specifically
target genetic mutations and signalling pathways altered
in lung cancer [4]. Up to now four targeted therapies have
been FDA-approved for the treatment of lung cancer.
Morevoer, the use of oncolytic viruses is a very promising
therapeutic approach for the treatment of cancer. These
viruses, either naturally occurring or genetically engineered,
are replication-competent viruses that are able to selectively
infect and destroy cancer cells either after intratumoral or
systemic administration [5]. Among the most intensively in-
vestigated oncolytic viruses in preclinical or clinical studies
are adenoviruses, herpes simplex virus, Newcastle disease
virus, measles virus and Vaccinia virus [6-8]. Vaccinia virus
(VACV) is a very promising agent for oncolytic virotherapy,
since the use of VACV as a vaccine during the eradication
of smallpox clearly demonstrated its safety in human
patients. Furthermore, the broad host range, the efficient
replication exclusively in the cytoplasm of host cells, the
natural tropism for tumor tissues, and its large genome
with a huge capacity for the integration of recombinant
DNA are further advantages over other oncolytic viruses
[9,10]. Until now, various oncolytic VACV have been
investigated in preclinical and clinical studies [11]. Recently,
it was shown that an oncolytic VACV, GLV-1h68, which
was constructed by inserting gene expression cassettes for a
Renilla luciferase-Aequora green fluorescent fusion protein
(RUC-GFP), β-galactosidase and β-glucuronidase into the
F14.5 L, J2R, and A56R loci, respectively, possesses reduced
toxicity and enhanced tumor targeting specificity compared
with its parental LIVP strain [12]. We have demonstrated
that treatment with GLV-1h68 or its derivatives led to inhib-
ition of tumor growth in several different xenograft models,
including human breast cancer [12-14], anaplastic thyroid
carcinoma [15], malignant pleural mesothelioma xenografts
[16], squamous cell carcinoma [17], pancreatic carcinoma
[18-21], prostate carcinoma [22-24], lung carcinoma [24],
fibrosarcoma [25], hepatocellular carcinoma [26] as well as
canine mammary adenoma [27] and carcinoma [28]. In
addition, two clinical trials with GL-ONC1 (clinical gradeGLV-1h68) have been successfully started (http://www.clini-
caltrials.gov; references NCT00794131 and NCT01443260).
Due to limitiations of oncolytic tumor therapy observed
in several clinical studies, various approaches to enhance
the efficiency of oncolytic viruses e.g. by combination with
different cancer treatment modalities such as chemotherapy
or radiotherapy are currently intensively investigated [29].
Improved results have been observed for GLV-1h68 using
combinations with cisplatin or gemcitabine in pancreatic
[18], mitomycin C in prostate [23] or the β-galactosidase-
activatable prodrug seco-analog of duocarmycin SA in
breast tumor xenografts [14]. Moreover, systemically de-
livered GLV-1h68 in combination with focal ionizing radi-
ation (IR) resulted in improved tumor growth inhibition
and mouse survival in a glioma tumor model [30].
Cyclophosphamide (CPA) is an alkylating agent that is
known to cause crosslinking of DNA and is used for treat-
ment of various tumors. CPA per se is an inactive prodrug
that requires metabolic activation in the liver to become
the active compound 4-hydroxycyclophosphamide. CPA
has already been applied in combination with oncolytic
viruses in various tumor models and its synergistic effects
have been observed with Herpes simplex virus in glioma
models [31-34], sarcoma [35] or in lung adenocarcinoma
[36], with adenovirus in a hamster model of renal adeno-
carcinoma [37] and in cancer patients [38], with Reovirus
in mouse melanoma [39,40], and with VACV in a glioma
xenograft model [41].
In this study, we set out to evaluate the oncolytic ac-
tivity of GLV-1h68 in the human lung adenocarcinoma
cell line PC14PE6 in cell culture, as well as to determine
the antitumor potency of GLV-1h68 as monotherapy or in
combination with CPA in a mouse model of PC14PE6-RFP
lung adenocarcinoma. Our results demonstrate that GLV-
1h68 is able to replicate in and kill human PC14PE6-RFP
cells in cell culture. Furthermore, GLV-1h68 efficiently
colonizes and notably delays the growth of PC14PE6-RFP
tumors in a xenograft mouse model. Moreover, combin-
ation therapy with CPA and GLV-1h68 significantly im-
proves the antitumoral efficacy of systemically injected
GLV-1h68. Higher levels of pro-inflammatory cytokines
and chemokines are seen in tumors of GLV-1h68-treated
mice, while after CPA or combination treatment factors
either expressed by endothelial cells or present in the blood
are found to be reduced. Moreover, combination treatment
led to a loss of the hemorrhagic phenotype of PC14PE6-
RFP tumors. Our results strongly suggest that the enhanced
tumor control achieved by combining GLV-1h68 with CPA
is due to an action of CPA on the tumor vasculature.
Methods
Cell lines and virus strain
Stably dsRed2-expressing human PC14PE6 cells were engi-
neered and kindly provided by the group of F. Winkler
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Germany) in 2008 [42]. This PC14PE6-RFP cells were
authenticated by the Leibniz-Institut DSMZ (Deutsche
Sammlung von Mikroorganismen und Zellkulturen GmbH,
Braunschweig, Germany) to be identical with the parental
cell line PC14 (Riken, Japan) in 2012. PC14PE6-RFP cells
were maintained in DMEM (PAA Laboratories, Cölbe,
Germany) supplemented with 10% fetal bovine serum
(FBS), 2 mM GlutaMAX (both from Invitrogen GmbH,
Karlsruhe, Germany), 1× non-essential amino acids, 1×
penicillin/streptomycin (both from PAA Laboratories) at
37°C under 5% CO2. African green monkey kidney fibro-
blasts (CV-1; ATCC number CCL-70) were cultured in
growth medium consisting of DMEM with 10% FBS and
1x penicillin/streptomycin at 37°C under 5% CO2. The
attenuated Vaccinia virus strain GLV-1h68 was derived
from LIVP (Lister strain from the Institute of Viral prepa-
rations, Moscow, Russia), as described previously [12].Viral replication assay
For the viral replication assay, PC14PE6-RFP cells grown
in 24-well plates were infected with GLV-1h68 at MOI
0.1 or 1.0 in infection medium (DMEM containing 2%
FBS and supplements). After one hour of incubation at
37°C with gentle agitation every 20 min, virus-containing
supernatants were removed and replaced by fresh growth
medium. After 24, 48 or 72 h, cells and supernatants were
harvested. Following three freeze-thaw cycles, serial dilu-
tions of the lysates were titered by standard plaque assays
on CV-1 cells. All samples were measured in triplicate.Cell viability assay
To determine viral cytotoxicity, GLV-1h68 infected and
uninfected PC14PE6-RFP cells in 24-well plates were
analyzed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) assay. Cells were infected
with GLV-1h68 at MOI 0.1 or 1.0 or mock-infected with
infection medium (DMEM containing 2% FBS and supple-
ments). After one hour of incubation, virus-containing
supernatants were removed by aspiration and fresh
medium was added. After 24, 48 and 72 h, respectively,
media were removed and 500 μl MTT (2.5 mg/ml, Sigma-
Aldrich, Germany) solution in DMEM without phenol red
(PAA Laboratories, Cölbe, Germany) was added for 2 h
at 37°C and 5% CO2. MTT solution was then removed
and 400 μl of 1 N HCl in isopropanol was added. Each
sample (3×100 μl) was transferred to a 96-well plate
and absorbance was measured at 570 nm with a reference
wavelength of 650 nm in a Sunrise Microplate reader
(Tecan, Austria). The percentage of cell survival was
calculated using the following formula: % cell survival =
(absorbance value of infected cells/absorbance value of
uninfected control cells) × 100%.Human tumor xenografts and virus injections
All animal experiments were performed in accordance with
protocols approved by the government of Unterfranken
(Wuerzburg, Germany, protocol number AZ 55.2-2531.01-
17/08) or by the Institutional Animal Care and Use
Committee (IACUC) of Explora Biolabs (San Diego, USA,
protocol number EB11-025). Human PC14PE6-RFP cells
(4×105 cells in 100 μl PBS) were implanted subcutaneously
into the right flank of six-week-old female nude mice (Hsd/
Athymic Nude-Foxn1nu, Harlan Laboratories, Netherlands
and Indianapolis). Tumor growth was monitored twice a
week using a digital caliper. Tumor volume was calculated
with the following formula: [(length × width2) × 0.52].
When tumors reached 100–200 mm3 mice were either
injected via the tail vein with 1×107 pfu GLV-1h68 (in
100 μl PBS) or PBS as control and/or combination
treatment was started (day 0). For cyclophosphamide
(CPA) combination treatment groups of infected or
uninfected mice were injected intraperitoneally with
140 mg/kg bodyweight CPA (Sigma-Aldrich, Germany)
at day 0, and with 100 mg/kg bodyweight CPA at days
1, 3, 7, 10, 15, 18 and 21.
Virus titration from tumors and organs
To assess viral distribution, PC14PE6-RFP tumor-bearing
mice were either infected via tail vein with 1×107 pfu of
GLV-1h68 (in 100 μl PBS) or subjected to combination
treatment. At indicated time points, mice were sacrificed
and tumors and organs were prepared and weighted. Tu-
mors were homogenized in an gentleMACS Dissociator
using M-Tubes (both Miltenyi Biotech GmbH, Bergisch
Gladbach, Germany) and organs in Precellys tubes (Peqlab,
Erlangen, Germany) in a FastPrep™ FP120 (Thermo Electron
Corporation, Langenselbold, Germany). After three freeze-
thaw cycles, viral titers in homogenates were determined
by standard plaque assays on CV-1 cells.
Fluorescence live-animal imaging
Tumor cell growth and viral infection were monitored
directly by optical imaging based on dsRed-expression
by tumor cells and GFP-expression by virus infected cells
respectively and quantified using a Maestro EX imaging
system (CRI, Woburn, MA). Mice were anesthetized by
isofluran inhalation (induction 4%, maintenance 1%).
Images were taken at days 14 and 21 with a Maestro EX
imaging system (CRi, Woburn, MA) using appropriate fil-
ters for dsRed (tumor, excitation: 503–555 nm, emission:
580 nm cut-in) and GFP (virus, excitation: 445–490 nm,
emission: 515 nm cut-in). Images were evaluated and
quantified using the Maestro Version 2.10.0 software.
Rodent multi-analyte profile
For preparation of tumor lysates, three mice of each group
were sacrificed 7 dpi. Tumors were removed, resuspended
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(pH 7.4); 2 mM EDTA (pH 7.4), 2 mM PMSF and
Complete Mini protease inhibitors (Roche, Mannheim,
Germany) and lysed in an gentleMACS Dissociator
using M-Tubes (both Miltenyi Biotech GmbH, Bergisch
Gladbach, Germany). Samples were then centrifuged at
500 g at 4°C for 5 min and supernatants were submitted
to Rules-Based Medicine (Myriad RBM, Austin, USA) for
bead-based immunodetection of mouse immune-related
protein antigens (RodentMAP® v2.0).
Immunohistochemistry
For immune-histochemistry, tumors were excised and
snap-frozen in liquid N2, followed by fixation in 4%
paraformaldehyde/PBS pH 7.4 for 16 h at 4°C. Fixed
tumors were dehydrated in 10% Sucrose/PBS for 3–4 h
followed by 30% sucrose/PBS for 12 h and finally embedded
in Tissue-Tek® O.C.T. (Sakura Finetek Europe B.V., Alphen
aan den Rijn, Netherlands). Tumor samples were sectioned
(15 μm) with the cryostat 2800 Frigocut (Leica Microsys-
tems GmbH, Wetzlar, Germany) and stored at −80°C.
Antibody-labeling was performed following fixation in
ice-cold aceton. Endothelial cells were labelled with the
hamster anti-mouse CD31 antibody (Chemicon, Inter-
national, Temecula, CA) and Cy3-conjugated secondary
donkey anti-hamster antibody obtained from Jackson
ImmunoResearch (West Grove, PA). The primary anti-
body was incubated for 1 h. After washing with PBS, sec-
tions were labeled for 30 min with the secondary
antibody and finally mounted in Mowiol 4–88.
Fluorescence microscopy
The fluorescence-labelled preparations were examined
using the Leica TCS SP2 AOBS confocal laser microscope
equipped with an argon, helium-neon and UV laser and
the LCS 2.16 software (1024 × 1024 pixel RGB-color
images). Digital images were processed with Photoshop
7.0 (Adobe Systems, Mountain View, CA) and merged
to yield overlay images.
Measurements of microvessel density
The vascular density was determined in microscopic im-
ages (×20 objective, ×10 ocular) of CD31-labelled tumor
sections. On the confocal microscope, the CD31 fluores-
cence was set to a clearly detectable level by adjusting
the photo-multiplier before the images were captured.
All images were decorated with five horizontal lines at
identical positions using Photoshop 7.0 and all vessels
which intersected these lines were counted to yield the
vascular density. The vascular density was calculated in
duplicate for ten images (five images of two different con-
trol, GLV-1h68-infected or combination-treated tumors)
and presented as mean values with standard deviations.Statistics
A two-tailed Student’s t test was used for statistical analysis.
P values of < 0.05 were considered statistically significant.
Results
Human lung adenocarcinoma PC14PE6-RFP cells are
permissive to infection with vaccinia virus GLV-1h68
In order to determine the infectivity of GLV-1h68 for
the human lung adenocarcinoma cell line PC14PE6, we
examined the kinetics of the GLV-1h68 replication in this
cell line. Accordingly, PC14PE6-RFP cells were infected
with GLV-1h68 (multiplicity of infection (MOI) 0.1 or
1.0), and a time-course analysis of viral replication was
performed. A 2- to 3-fold logarithmic increase of GLV-
1h68 titers in PC14PE6-RFP cells within 72 hours post
infection (hpi) was observed at both MOIs (Figure 1A),
demonstrating that the oncolytic Vaccinia virus GLV-
1h68 is able to efficiently replicate within the human lung
adenocarcinoma cells in cell culture. Next, we analyzed
the oncolytic efficacy of GLV-1h68 on PC14PE6-RFP cells
by a MTT cell viability assay. The results revealed that 24
hpi the number of surviving cells markedly decreased in
an MOI-dependent manner. At 72 hpi, only 41+/−9.7% or
17+/−10.2% of cells survived the treatment at MOI 0.1 or
1.0, respectively, demonstrating the considerable cytotoxic
effect of GLV-1h68 on PC14PE6-RFP cells. Taken to-
gether, these data indicate that GLV-1h68 productively
infects, replicates in and lyses human PC14PE6-RFP cells
in cell culture, suggesting that GLV-1h68 has the potential
to treat PC14PE6-RFP tumors in a mouse model.
GLV-1h68 efficiently colonizes PC14PE6-RFP tumors in a
xenograft mouse model
Next, we investigated the biodistribution of systemically
injected GLV-1h68 in PC14PE6-RFP tumor-bearing nude
mice. For that, homogenates of tumors and organs from
intravenously injected (1x107 plaque-forming units (pfu))
PC14PE6-RFP tumor-bearing mice (n = 4) were titered on
CV-1 cells three, seven and 14 days after injection
(Table 1). GLV-1h68 localized primarily to the tumors (in
4/4 mice per group) and was either not detectable (in liver,
spleen) or found at notably lower titers in normal tissues
(either in 1/4 or 2/4 mice, in lungs, ovaries or brain).
Within three days post infection 3.5×107+/−3.15×106 pfu
GLV-1h68/g tissue were found in tumors. The highest
viral load in tumors was detected 14 days post infection,
on average 3.44×108+/−1.85×107 pfu/g tumor tissue.
These data suggest that GLV-1h68 has a strong selectivity
towards PC14PE6-RFP tumors in nude mice.
GLV-1h68 treatment significantly delays tumor growth in
PC14PE6-RFP bearing nude mice
Due to the observed oncolytic effect of GLV-1h68 on
PC14PE6-RFP cells in cell culture and the massive
Figure 1 GLV-1h68 replicates in and kills human PC14PE6-RFP cells in cell culture. (A) Virus titers were determined from PC14PE6-RFP cells
infected with GLV-1h68 at indicated MOIs. (B) MTT assays were performed on PC14PE6-RFP cells infected with GLV-1h68 with indicated MOIs.
Data are presented as percentage of control cells +/− s.d.
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we analyzed the PC14PE6-RFP tumor growth response
to oncolytic virotherapy with GLV-1h68 in vivo. For that,
4×105 PC14PE6-RFP cells were implanted s.c. into the
right flank of nude mice. Tumor-bearing mice (n = 6)
were i.v. injected with 1×107 pfu GLV-1h68 or with PBS
as control. Tumor growth was monitored and already
ten days post injection a significant tumor growth delay
(p < 0.01) of the GLV-1h68 treated group compared to
the PBS group was observed (Figure 2). After this time
point all mice of the control group had to be sacrificed
due to high tumor burden. Despite an initial response
to therapy, in the course of the experiment tumors of
GLV-1h68-treated mice showed steadily tumor growth.
Moreover, starting with day 20, individual mice of theTable 1 Distribution of GLV-1h68 virus particles in tissues
of PC14PE6-RFP tumor-bearing nude mice
Distribution of GLV-1h68 in tissues of
PC14PE6-RFP tumor-bearing nude mice
Tissue pfu/g of tissue (n = 4)
3 dpi 7 dpi 14 dpi
Tumor 3.5x107+
/−3.15x106 (4/4)
1.91×108+
/−3.21×106 (4/4)
3.44×108+
/−1.85×107 (4/4)
Liver 0 0 0
Spleen 0 0 0
Lungs 0 2.14×103+
/−8.04×102 (1/4)
5.04×101+
/−1.22×101 (2/4)
Ovaries 0 3.4×103+
/−2.04×103 (1/4)
9.61×103+
/−1.86×104 (2/4)
Brain 0 0 1.96×102+
/−1.58×102 (1/4)
PC14PE6-RFP tumor-bearing nude mice (n = 4) were infected with 1×107 pfu
of GLV-1h68. Three, seven and 14 days after infection, tumors and organs were
harvested and viral titers were determined by standard plaque assays on CV-1
cells. Results are shown as mean pfu/g tissue or organ +/− s.d.GLV-1h68 treated group had to be taken out of the ex-
periment due to excess tumor volume.
Cyclophosphamide significantly improves the antitumoral
efficacy of systemically injected GLV-1h68
Since we have seen that treatment with GLV-1h68 leads
to a significant tumor growth delay in the PC14PE6-RFP
xenograft model but unfortunately neither tumor regres-
sion nor stable disease could be achieved by this therapy,
we set out to improve the outcome of the therapy by
combining oncolytic virotherapy with chemotherapy using
cyclophosphamide (CPA). For that, nude mice bearing
subcutaneously implanted PC14PE6-RFP tumors either
received a single i.v. injection of 1×107 pfu GLV-1h68
or an i.p. injection of 140 mg/kg/bw CPA at day 0,
followed by multiple i.p. injections of 100 mg/kg/bw every
3–4 days during the whole experiment or a combination
of viro- and chemotherapy (n = 5; Figure 3A). In PBS
treated control mice rapid tumor growth was observed,
reaching the tumor end point between ten and 14 days
post treatment initiation (Figure 3B). Therapy with CPA
alone resulted in a slight delay of tumor growth compared
to control mice. Treatment with oncolytic GLV-1h68
resulted in a more pronounced tumor growth retard-
ation being significant from day seven post injection on
(p < 0.05, day 7; p < 0.01, day 10). Mice of this group
reached highest acceptable tumor volumes on day 28
after start of therapy. In marked contrast, combination
treatment showed an impressive antitumor activity. The
tumor growth retardation after combination treatment was
significant compared to the PBS control group starting day
seven (p < 0.05, day 7; p < 0.01, day 10) and compared to
CPA alone from 14 days post injection on (p < 0.05, days 14
and 17). Even more, beginning with day 21 combination
treatment had a significant better effect on the growth of
Figure 2 Treatment of PC14PE6-RFP xenografts by a single i.v. injection of GLV-1h68. 4×105 PC14PE6-RFP cells were implanted subcutaneously into
the right flank of female nude mice. When tumor volumes reached approximately 200–250 mm3 mice were randomized into two groups (n = 6). Mice
were either treated with an i.v. injection of 1×107 pfu GLV-1h68 or received PBS as control (day 0). Numbers of surviving mice are indicated in parentheses.
Figure 3 Combination treatment of PC14PE6-RFP tumor-bearing nude mice with GLV-1h68 and cyclophosphamide. (A) Treatment
schedule demonstrating the regimen of GLV-1h68 and CPA treatment in PC14PE6-RFP tumor-bearing mice. (B) Tumor volumes of PC14PE6-RFP
tumors treated with or without combination treatment. 4×105 PC14PE6-RFP cells were implanted subcutaneously into the right flank of female
nude mice. When tumor volumes reached approximately 100–130 mm3 mice were randomized into four groups (n = 5). Mice were either treated
with a single i.v. injection of 1×107 pfu GLV-1h68, with multiple i.p. injections of CPA, a combination of both or with PBS as control. Numbers of
surviving mice are indicated in parentheses.
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(p < 0.05, days 21 and 24; p < 0.01, day 28) with stable
tumor volume until 32 days. Over the course of the experi-
ment no evident toxicity by either treatment was seen, as
confirmed by monitoring of body weight (data not shown).
These results demonstrate that CPA in combination with
GLV-1h68 acts synergistically in PC14PE6-RFP xenografts
and is promising for future clinical applications.
Treatment with CPA does not alter viral titers in tumors
and organs of nude mice
To address whether the increased antitumor efficacy of
the combination therapy is associated with higher viral
titers in the tumors or CPA exerts an immunosuppressive
effect in our experimental model possibly resulting in
elevated viral load in organs, we prepared tumors and
organs of GLV-1h68-treated as well as GLV-1h68- and
CPA-treated mice 21 days post infection and determined
titers by plaque assays. Interestingly, combination treatment
does not significantly alter the amounts of viral particles in
the tumor compared to treatment with GLV-1h68 alone
(Table 2). Furthermore, we did not see increased viral
titers in the organs of mice after combination treatment,
suggesting that in our experimental model treatment with
CPA has no immunosuppressive effect leading to systemic
infection with Vaccinia virus.
CPA treatment results in infection of larger tumor areas
To analyze the intratumoral viral distribution as well as
the extent of the viral tumor infection, we investigated
live tumor-bearing mice 14 and 21 days after beginning
of treatment by fluorescence imaging (Figure 4A and B).
For this, the tumor mass was measured via the RFP
fluorescence of the tumor cells and the viral infection
was determined by GFP expression. The RFP signalsTable 2 Distribution of GLV-1h68 virus particles in tissues
of PC14PE6-RFP tumor-bearing nude mice treated with
GLV-1h68 or GLV-1h68/CPA
Distribution of GLV-1h68 in tissues of PC14PE6-RFP tumor-bearing
nude mice, 21 dpi
Tissue pfu/g of tissue (n = 3)
GLV-1h68-treated mice GLV-1h68- and CPA-treated mice
Tumor 6.35×108+/−9.01×107 (3/3) 1.42×108+/−5.1×106 (3/3)
Liver 0 0
Spleen 0 0
Lungs 2.63×102+/−9.43 (1/3) 0
Ovaries 1.51×104+/−3.06×102 (2/3) 7.28×104+/−1.15×103 (1/3)
Brain 0 0
PC14PE6-RFP tumor-bearing nude mice (n = 3) were either infected solely with
1×107 pfu of GLV-1h68 or infected with GLV-1h68 and received simultaneous
treatment with CPA. 21 days after infection, tumors and organs were harvested
and viral titers were determined by standard plaque assays on CV-1 cells. Results
are shown as mean pfu/g tissue or organ +/− s.d.obtained by fluorescence imaging (Figure 4C) correlated
well with tumor size measurements shown in Figure 3.
Twenty-one days post infection GFP signals in GLV-
1h68-treated mice were similar to the combination group
confirming the results found by plaque assays of homoge-
nized tumors (Table 2). Finally, the percentage of infected
tumor mass was calculated (Figure 4D). Strikingly, com-
bination treatment leads to a higher percentage of the
tumor mass infected (55.68%) compared to monotherapy
with GLV-1h68 (22.48%) 21 dpi. Thus, simultaneous treat-
ment with CPA led to a more pronounced viral distribu-
tion within the tumor tissue and, therefore, contingently,
to a better oncolytic effect in PC14PE6-RFP tumors.Analysis of the host immune response upon treatment
with virus and/or CPA
Since CPA is known as a broad immunosuppressive agent,
we investigated the host immune response to virus
infection and/or CPA treatment 7dpi in PC14PE6-RFP
tumor-bearing mice. We are aware of the fact that nude
mice lack adaptive immunity and results obtained by
these experiments might not be directly transferred to
immunocompetent humans. Nevertheless, we used the
nude mouse model since we wanted to study the oncolytic
effect of Vaccinia virus on a lung adenocarcinoma of
human origin. By protein profiling we found that expres-
sion levels of several cytokines and chemokines were
significantly elevated in tumors of GLV-1h68-treated mice
compared to untreated controls (Table 3A). The majority
of these cytokines and chemokines, like eotaxin, IL-7,
MIP-1 beta, MCP-1, MCP-3, MCP-5, or TNF-alpha, and
even Myeloperoxidase secreted by neutrophils and tissue
macrophages, create a pro-inflammatory microenviron-
ment in the target tissues. The only protein that was
found to be down-regulated upon viral infection was EGF,
a growth factor stimulating the growth of epidermal or
epithelial tissues and some fibroblasts.
Combination treatment leads to significant up-regulation
of M-CSF-1, MCP-1 and MCP-5 (pro-inflammatory) and
down-regulation of Apo A-I (anti-inflammatory) and EGF
(Table 3B) compared to untreated controls. Interestingly,
levels of VCAM-1 (expressed on endothelial cells during
inflammation) and coagulation factors Fibrinogen and
vWF are also significantly decreased after combination
treatment.
Compared to CPA treatment alone, infection with GLV-
1h68 or combination treatment leads to up-regulation
of several pro-inflammatory cytokines and chemokines
(Table 3C and D), like seen in the virus-treated versus
untreated tumors, affirming that virus infection results
in a pro-inflammatory status within the tumor. More-
over, compared to monotherapy with CPA, VCAM-1 is
decreased upon combination treatment. Interestingly, after
Figure 4 Imaging of live animals. Mice were imaged at 14 (A) or 21 (B) days post initiation of treatment. The images show the tumor area of
four representative mice of each group. At the left side of each unit an overlay of white light images of the mice and fluorescence images (RFP: tumor;
GFP: infection) are shown. On the top right side separate RFP signals respectively on the bottom right GFP signals are displayed. (C) Quantification of
tumor burden (RFP signals) and viral infection (GFP signals) by scaled counts/s. (D) Calculation of the percent of infected tumor area.
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Willebrand factor (vWF) are found (Table 3B, E and F).The hemorrhagic phenotype of PC14PE6-RFP tumors
disappears after combination treatment
We further could observe that especially untreated sub-
cutaneously implanted PC14PE6-RFP tumors but also
GLV-1h68- or CPA-treated tumors had a hemorrhagic
phenotype 7 dpi (Figure 5A), in striking contrast to tumors
after combination treatment, which appeared either white
or skin-colored. Notably, at the time point of infection,
tumors of the combination group have already been slightly
blue demonstrating that by treatment with GLV-1h68
in combination with CPA, tumors lose their hemorrhagic
phenotype. We finally analyzed the vascular density by
CD31 staining of tumor sections 7 dpi. Indeed, there was
a decrease in the number of blood vessels after CPA andcombination treatment compared to GLV-1h68-treated
tumors (Figure 5B), albeit this was not significant.
Discussion
The efficiency of the oncolytic VACV GLV-1h68 in treating
different human or canine cancers in mice has been dem-
onstrated in several preclinical studies [12-28]. Moreover,
currently two clinical trials with GLV-1h68 as intervention
are carried out (http://www.clinicaltrials.gov). One great ad-
vantage of oncolytic viruses for the treatment of cancers
comprises their capability to specifically kill cancerous cells
whereas normal cells are not affected. In the current study,
we investigated the effect of a combined treatment strategy
consisting of oncolytic VACV GLV-1h68 and the alkylating
agent CPA on the growth of human lung adenocarcinoma
PC14PE6 xenografts. Synergistic effects of diverse oncolytic
viruses and CPA have been described in the literature
[31-41]. Suggested mechanisms are, if specified, mostly due
Table 3 Comparison of mouse immune-related protein profiling in PC14PE6-RFP-derived tumors at day seven after
treatment begin (n = 3)
Antigen names Ratiosa Classification
(A) GLV-1h68/PBS
Eotaxin 9.34* Proinflammatory chemokine
Interleukin-11 (IL-11) 1.90* Cytokine
Interleukin-2 (IL-2) 1.97* Cytokine
Interleukin-7 (IL-7) 1.63* Proinflammatory cytokine
Macrophage Inflammatory Protein-1 beta (MIP-1 beta) 3.76* Proinflammatory chemokine
Monocyte Chemotactic Protein 1 (MCP-1) 18.30** Proinflammatory chemokine
Monocyte Chemotactic Protein 3 (MCP-3) 11.12** Proinflammatory chemokine
Monocyte Chemotactic Protein-5 (MCP-5) 27.85* Proinflammatory chemokine
Myeloperoxidase (MPO) 3.99** Peroxidase enzyme
Oncostatin-M (OSM) 1.99* Cytokine
Tumor Necrosis Factor alpha (TNF-alpha) 2.05* Proinflammatory cytokine
Epidermal Growth Factor Mouse (EGF Mouse) 0.54* Growth factor
(B) GLV-1h68 + CPA/ PBS
Macrophage Colony-Stimulating Factor-1 (M-CSF-1) 1.69* Proinflammatory cytokine
Monocyte Chemotactic Protein 1 (MCP-1) 20.16* Proinflammatory chemokine
Monocyte Chemotactic Protein-5 (MCP-5) 30.60* Proinflammatory chemokine
Apolipoprotein A-I (Apo A-I) 0.17* Anti-inflammatory protein
Epidermal Growth Factor Mouse (EGF Mouse) 0.54* Growth factor
Fibrinogen 0.52* Blood coagulation
Vascular Cell Adhesion Molecule-1 (VCAM-1) 0.45* Cell-cell adhesion
von Willebrand factor (vWF) 0.39* Blood coagulation
(C) GLV-1h68/CPA
Eotaxin 12.43* Proinflammatory chemokine
Granulocyte Chemotactic Protein-2 Mouse (GCP-2 Mouse) 2.51* Proinflammatory chemokine
Growth-Regulated Alpha Protein (KC/GRO) 2.96* Proinflammatory chemokine
Interleukin-10 (IL-10) 2.74* Cytokine
Interleukin-12 Subunit p70 (IL-12p70) 2.11* Pleiotropic cytokine
Macrophage Inflammatory Protein-1 beta (MIP-1 beta) 3.06* Proinflammatory chemokine
Macrophage Inflammatory Protein-3 beta (MIP-3 beta) 2.90** Proinflammatory chemokine
Matrix Metalloproteinase-9 (MMP-9) 2.30* Enzyme
Monocyte Chemotactic Protein 1 (MCP-1) 9.76** Proinflammatory chemokine
Monocyte Chemotactic Protein 3 (MCP-3) 5.90** Proinflammatory chemokine
Monocyte Chemotactic Protein-5 (MCP-5) 20.97* Proinflammatory chemokine
(D) GLV-1h68 + CPA/CPA
Granulocyte Chemotactic Protein-2 Mouse (GCP-2 Mouse) 3.05* Proinflammatory chemokine
Interleukin-6 (IL-6) 5.01* Cytokine
Monocyte Chemotactic Protein 1 (MCP-1) 10.75* Proinflammatory chemokine
Monocyte Chemotactic Protein-5 (MCP-5) 23.04* Proinflammatory chemokine
Serum Amyloid P-Component (SAP) 1.38* Acute phase reactant
T-Cell-Specific Protein RANTES (RANTES) 3.32* Proinflammatory chemokine
Tissue Inhibitor of Metalloproteinases 1 Mouse (TIMP-1 Mouse) 2.56* Protein inhibitor
Vascular Cell Adhesion Molecule-1 (VCAM-1) 0.78* Cell-cell adhesion
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Table 3 Comparison of mouse immune-related protein profiling in PC14PE6-RFP-derived tumors at day seven after
treatment begin (n = 3) (Continued)
(E) CPA/PBS
von Willebrand factor (vWF) 0.48* Blood coagulation
(F) GLV-1h68 + CPA/GLV-1h68
von Willebrand factor (vWF) 0.55** Blood coagulation
Note: All ratios greater than 1 indicate an up-regulation of protein expression, and all ratios less than 1 indicate down-regulation. aSignificant modification in
protein ratios with *p < 0.05, **p < 0.01, ***p < 0.001, Student’s t -test.
Hofmann et al. Journal of Translational Medicine 2014, 12:197 Page 10 of 14
http://www.translational-medicine.com/content/12/1/197to the immuno-modulatory properties of CPA. CPA is
known to suppress the host innate immunity and inhib-
ition of intratumoral infiltration of mononuclear cells has
been described, thus probably extending the survival of
the virus within the tumors [33,36,37]. When used in a
low- dose metronomic (LDM) schedule, CPA can also,
exert antiangiogenic effects [43-45].This seems to be based
on the induction of thrombospondin-1 which in turn prob-
ably acts antiangiogenic through binding to CD36 [46] or
through binding and sequestering VEGF [47].
In our study, we could show that combination therapy
with GLV-1h68 and CPA led to a significant growth in-
hibition of PC14PE6-RFP xenografts compared to GLV-
1h68 alone from day 21 post injection on (Figure 3B).
Analysis of the viral load of combination-treated or GLV-
1h68-treated tumors revealed that the better therapeutic
effect was not due to an enhanced viral titer in the tumors.Figure 5 Phenotypes of s.c. implanted PC14PE6-RFP tumors and num
subcutaneously implanted PC14PE6-RFP tumors were taken 7 days post PB
density was measured in CD31-labelled cross-sections of GLV-1h68-, CPA- o
the mean values +/− s.d.Moreover, after combination treatment we did not see
enhanced viral titers in the organs of mice suggesting
that CPA has no immunosuppressive effect in our experi-
mental model. Immune-related effects of the investigated
therapy were not explored in detail in the present study.
However, preliminary data obtained by histological ana-
lysis of CPA- and non-CPA-treated tumors 7 dpi revealed
no significant difference in the content of CD68-positive
immune cells, e.g. monocytes/macrophages (Additional
file 1). Furthermore depletion of phagocytic cells especially
monocytes and macrophages by clodronate liposomes
did result in lesser tumor growth retardation than by
treatment with CPA alone (Additional file 2). Both observa-
tions are again hinting that CPA has no effect on cells of
monocytic origin in the PC14PE6-RFP model. By protein
profiling of lysates of untreated, CPA-, GLV-1h68- and
combination treated tumors, we found the expression ofber of CD31-positive blood vessels. (A) Photographic images of
S-, GLV-1h68-, CPA- or combination treatment begin. (B) Vascular
r combination treated tumors 7 days after treatment start. Shown are
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host origin to be up-regulated in tumor tissues after
virus infection and even after combination treatment,
although to a lesser extent (Table 3). The majority of these
cytokines/chemokines and pro-inflammatory proteins, like
eotaxin, MIP-1 beta, MCP-1, MCP-3, MCP-5, TNF-alpha,
and MPO are known to be produced by activated macro-
phages in the inflamed tissue. Similar results also have
been obtained in xenograft models of human pancreatic
[18], prostate [22] and hepatocellular [26] as well as canine
mammary carcinomas [28] suggesting that it is a general
mechanism of GLV-1h68 to induce strong innate host
immune responses in tumors of different origins. It is
also very interesting to note that after virus infection or
combination treatment the CCR5 ligands MIP-1 beta/
MIP-3 beta or RANTES, respectively, are overexpressed.
The CCR5 ligand chemokine pathway is, among other
molecular pathways, known to be consistently activated
during immune-mediated cancer rejection as well as other
immune-mediated tissue destruction processes, as de-
scribed in the “Immunologic Constant of Rejection (ICR)”
[48]. The cytokine Oncostatin-M, which is up-regulated
after VACV infection, belongs to the IL-6 family and has
cytostatic activities on a number of tumor cell lines [49-51].
The only protein that was found to be down-regulated
upon viral infection was EGF. Interestingly, mutations of
the EGF receptor (EGFR) have been associated with several
types of cancers, including lung cancer, and targeted ther-
apy using small molecules disrupting kinase activity of
EGFR results in considerable clinical benefit in lung
cancer patients [4]. Moreover, Goswami et al. [52] de-
scribed a paracrine loop between breast carcinoma cells
(producing CSF) and macrophages (producing EGF)
leading to increased carcinoma cell invasion and they
suggested that disabling this loop might result in clinical
benefit in the treatment of cancer. So, it is remarkable that
by virotherapy with Vaccinia virus endogenous EGF levels
are reduced possibly resulting in inhibition of downstream
pro-survival signaling pathways or inhibition of tumor
cell invasion.
Combination treatment of GLV-1h68 and CPA leads to
significant up-regulation of M-CSF-1, MCP-1 and MCP-5,
which have pro-inflammatory activities (Table 3B) and
again to down-regulation of EGF compared to untreated
controls. Concentrations of Apo A-I, VCAM-1, Fibrino-
gen and vWF are found to be decreased after combination
treatment. Apo A-I has anti-inflammatory [53,54] but
also anti-thrombotic [55] activities. VCAM-1 is expressed
by the cytokine-activated endothelium and mediates
leukocyte-endothelial cell adhesion. It is also known
that in several types of cancers VCAM-1 is aberrantly
expressed on the surface of tumor cells thereby tethering
macrophages to tumor cells and generating favorable
conditions for tumor angiogenesis, invasion and metas-tasis [56,57]. Recently, a study reported about an EGF-
enhanced VCAM-1 expression promoting macrophage
and glioblastoma cell interaction and tumor cell invasion
[57]. In another work a VCAM-1-mediated tumor immune
evasion has been described [58,59]. The authors found that
overexpression of VCAM-1 by cancer cells led to decreased
apoptosis of tumor cells and a significant decrease in
the number of tumor-infiltrating CD8+ T cells expressing
VCAM-1. Therefore, reduction of VCAM-1 and EGF by
combination treatment might have favorable effects in
terms of inhibition of tumor cell invasion and tumor
immune evasion. Fibrinogen plays a pivotal role in the
coagulation cascade. vWF is synthesized by endothelial
cells and megakaryocytes and promotes the adhesion of
platelets to sites of vascular injury. Interestingly, the latter
four factors, Apo A-I, VCAM-1, Fibrinogen and vWF,
which are found to be decreased after combination
treatment, are either expressed by endothelial cells or
are present in the blood, hinting that combination therapy
has an effect on the tumor vasculature in the PC14PE6-
RFP model. Compared to CPA treatment alone, infection
with GLV-1h68 or combination treatment leads to an
up-regulation of several pro-inflammatory cytokines and
chemokines (Table 3C and D), like seen in the virus-treated
versus untreated tumors, affirming that virus infection
leads to a pro-inflammatory status within the tumor.
Moreover, compared to monotherapy with CPA, lower
levels of VCAM-1 are observed upon combination treat-
ment. Interestingly, after CPA or combination therapy the
only protein that was found to be significanlty decreased
compared to respective controls was vWF (Table 3E and
F). This indicates that the primary effect of CPA in this
model is caused by an effect on the vasculature and not by
alteration of the immune response. However, it is specu-
lating to assume if the lower levels of these factors are due
to a down-regulation on the level of protein expression or
are a result of the lower density of blood vessels found in
tumors after CPA or combination treatment.
Taken together, these data show that pro-inflammatory
cytokines and chemokines are elevated in PC14PE6-RFP
tumors of GLV-1h68-treated mice (Table 3A, B, C, and D).
But more importantly, levels of factors either expressed by
endothelial cells or present in the blood are found to be de-
creased after CPA or combination treatment (Table 3B, D,
E, and F). We therefore suppose that in the PC14PE6-RFP
model the enhanced tumor growth inhibition observed
after combination therapy is due to an effect on the vascu-
lature rather than an immunosuppressive action of CPA.
However, it is conceivable that the modulation of the vas-
culature may alter the following immunological response
to VACV e.g. by hampering immune recruitment to the
tumor site.
Especially untreated PC14PE6-RFP tumors, but also
GLV-1h68 or CPA-treated tumors have a hemorrhagic
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the PC14PE6 cell line since Yano et al. already described
the development of bloody pleural effusions after i.v.
injection of PC14PE6 cells [60]. Only recently, Weibel
et al. showed that after subcutaneous implantation of
PC14PE6 cells malignant effusion concomitant hematoma
formation occurs at the tumor site, and, during oncolytic
virotherapy using GLV-1h68 and especially its derivative
GLV-1h108, which encodes a single chain antibody against
VEGF, tumor-associated hematoma disappeared [61].
Remarkably, in the present study we could show that
after combination treatment PC14PE6-RFP tumors lose
their hemorrhagic phenotype. Since at the time point of
treatment start, tumors of the combination group already
showed a slight blue color, CPA treatment seems not only
to prevent the development of the hematoma but to
actively rebuild a non-hemorrhagic appearance when
used in combination with oncolytic Vaccinia virus GLV-
1h68. This additionally indicates that in the PC14PE6-RFP
xenograft model combination therapy with GLV-1h68 and
CPA acts on the tumor vasculature. To further support
this hypothesis, we analyzed the vascular density in
CD31-labelled tumor cross-sections 7 dpi. Indeed, there
was a decrease in the number of blood vessels after
CPA and combination treatment compared to GLV-1h68-
treated tumors (Figure 5B), albeit this was not significant.
The presence of CD31-positive blood vessels after CPA
treatment, further suggest that CPA seems to have no
immunosuppressive effect, since CD31 is involved in
leukocyte trafficking to sites of inflammation. Previous
work in our laboratory demonstrated that GLV-1h68
does not destroy endothelial cells in tumors and that
the tumor vasculature in infected tumors is still functional
[62]. In the matter of the significance of tumor vasculature
in tumor progression, therapeutic approaches additionally
targeting the tumor endothelium may contribute to a
better therapeutic outcome. Therefore, combination strat-
egies composed of an agent, which directly kills tumor
cells on the one hand (in our case GLV-1h68), and an
additional therapeutics, which targets normal cells within
the tumors, e.g. tumor vasculature, are particularly ad-
vantageous. In this study, such a combination therapy
consisting of oncolytic VACV GLV-1h68, destroying tumor
cells, and CPA, presumably targeting tumor vasculature,
could successfully be established for the PC14PE6-RFP
tumor model.
Conclusions
Our data demonstrate that combination treatment of GLV-
1h68 and CPA results in strongly enhanced antitumor effi-
cacy in the PC14PE6-RFP tumor model. Results presented
here suggest that improved tumor control achieved by
combining GLV-1h68 with CPA is due to the action of
CPA on the tumor vasculature. Yet, the effect of CPA maybe cancer cell specific as well as highly dose dependent and
may also be mouse model specific. Nevertheless, these re-
sults justify the design of additional preclinical studies in
other highly angiogenic tumor models. Moreover, the data
shown here demonstrate that CPA as a chemotherapeutic
agent can also be combined successfully with GLV-1h68
strain (GL-ONC1), which is currently evaluated in phase I/
II clinical trials as monotherapy and could be considered as
combination therapy in human clinical trials.
Additional files
Additional file 1: Histological analysis of CD68-positive immune
cells in PC14PE6-RFP tumors. PC14PE6-RFP tumor-bearing mice were
either i.v. injected with 1×107 pfu of GLV-1h68 or PBS as control and/or
received i.p. injections with 140 mg/kg bodyweight CPA at day 0 and
with 100 mg/kg bodyweight at days 1, 3 and 7. Tumors were harvested 7
dpi. (A) Whole tumor cross-sections of PBS-, CPA-, GLV1h68- or combin-
ation-treated tumors were labelled with an anti-rat CD68 antibody
(Abcam, Cambridge, UK) and a secondary DyLight 649-conjugated donkey
anti-rat antibody (Dianova, Hamburg, Germany) to visualize the presence
of CD68-positive leukocytes. All confocal images are representative examples
for respective groups. (B) Mean fluorescence intensity of CD68-labelling
was determined using Image J software (http://rsbweb.nih.gov/ij). For
all experiments the mean value was calculated for 12 images (four images
of three different PBS-, CPA-, GLV-1h68- or combination-treated tumors) and
presented as mean values with standard deviations.
Additional file 2: Depletion of phagocytic cells by clodronate
liposomes. PC14PE6-RFP tumor-bearing mice were either i.v. injected with
1×107 pfu of GLV-1h68 or PBS as control or received i.p. injections with 140
mg/kg bodyweight CPA at day 0 and with 100 mg/kg bodyweight at days
1, 3 and 7 or i.p. injections with 200 μl Clodronate liposomes (CLIP) at days
0, 1, 3 and 7 post treatment start. Clodronate liposomes were obtained from
clodronateliposomes.com (N. van Rooijen, Amsterdam, The Netherlands) at
a concentration of 7 mg/ml. Tumor growth was monitored for 14 days.
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